TB-500 UK legal status
TB-500 (a fragment of thymosin beta-4) sits alongside BPC-157 as one of the most heavily-marketed ‘research peptides’ for tissue repair. It is not a licensed UK medicine, and WADA treats it as a prohibited substance for athletes.
Current UK regulatory framing
TB-500 is a synthetic peptide derived from a fragment of thymosin beta-4, an endogenous regulatory peptide involved in actin polymerisation, cell migration, and angiogenesis. There is no UK marketing authorisation for TB-500 (or for thymosin beta-4 as a finished medicine).
As with all unlicensed peptides, “research only” labelling does not displace the medicinal-product analysis when the supply chain looks like consumer supply. See ‘not for human consumption’ claims.
The evidence base
The preclinical literature for thymosin beta-4 and its fragments covers wound healing, corneal repair, cardiac post-infarction remodelling, and skin regeneration in animal models. Human trial data is comparatively sparse; published trials have focused on specific indications (e.g. dry eye disease) and on the parent molecule rather than TB-500 specifically.
The gap between this evidence base and the marketing claims (“heals tendon and ligament injuries”, “recovers muscle tears in days”) is large. The grading on this site places TB-500 in the lower evidence bands.
Sport — WADA S2
Thymosin beta-4 and its fragments fall within S2 of the WADA Prohibited List (peptide hormones, growth factors, related substances, and mimetics). The category prohibits these substances at all times, both in and out of competition.
Strict liability applies. An athlete who tests positive for TB-500 metabolites cannot defend on the basis that they were using it “for injury recovery” or under research labelling. See athlete anti-doping risks.
What this means in practice
For sellers
Marketing TB-500 with human-use claims (tissue repair, injury recovery, faster healing) is the wording that brings medicinal-product analysis into play. The MHRA can act.
For clinics
A UK clinic offering TB-500 as a regenerative or performance-recovery service is offering an unlicensed product for a human-health purpose. The clinical-governance question (“what licensed medicine are you taking responsibility for?”) does not have a comfortable answer.
For consumers
Personal possession is not the primary enforcement target, but the safety, sterility, and identity-of-product risks are real and there is no licensed-medicine framework to fall back on. See unlicensed peptide risks.
For athletes
Don’t. Strict liability is unforgiving and the available metabolite tests for thymosin beta-4 mean detection is realistic.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“TB-500 + BPC-157 — the gold-standard healing stack”
Marketing language for two unlicensed peptides with no human RCT evidence for the combination. Both also have direct legal and anti-doping risk.
“Athlete-recovery peptide — back on the field in days”
Direct WADA strict-liability risk under S2. The marketing also implies a clinical-recovery outcome that the evidence base doesn't support.
“Pharma-grade TB-500 — UK shipping”
‘Pharma-grade’ is a marketing claim with no third-party verification in the grey-market peptide supply chain.
“Research-only — but full reconstitution and dosing guide included”
Consumer-supply presentation that contradicts the ‘research only’ disclaimer.
Sources & further reading
- MHRA — gov.uk
- Human Medicines Regulations 2012 — legislation.gov.uk
- WADA Prohibited List (S2 — Peptide Hormones and Growth Factors) — wada-ama.org
- WADA — Therapeutic Use Exemptions — wada-ama.org
- Global DRO — globaldro.com
Frequently asked questions
- Is TB-500 legal in the UK?
- TB-500 is not a licensed UK medicine. Supplying it as a medicine, or with claims that engage the medicinal-product definition, is unlawful under the Human Medicines Regulations 2012. Personal possession is a different question from supply, advertising, or import for supply.
- Is TB-500 prohibited in sport?
- Yes. Thymosin beta-4 and its fragments are treated as prohibited under S2 of the WADA Prohibited List (peptide hormones, growth factors, related substances, and mimetics). Strict liability applies regardless of intent.
- What's the evidence base for TB-500?
- Largely preclinical (animal studies) for tissue repair, wound healing, and cardiac protection. Robust human RCTs are lacking. Marketing claims about tendon, ligament, and muscle recovery exceed what the evidence supports.
- Can a UK clinic prescribe TB-500?
- TB-500 has no UK marketing authorisation. A clinic offering it as a regenerative or healing therapy is presenting an unlicensed product as a medicine, which engages MHRA's remit. There is no specials-framework route that easily reaches TB-500.
- Is TB-500 the same as thymosin beta-4?
- Not quite. Full thymosin beta-4 is a 43-amino-acid peptide; TB-500 is a synthetic fragment derived from it. The WADA classification covers both.